Immunization studies with attenuated strains of Bacillus anthracis

Area of Science:

• Microbiology and Immunology
• Vaccine Development
• Infectious Disease Research

Background:

• Bacillus anthracis causes anthrax, a severe disease.
• Live, attenuated vaccines are a potential strategy for anthrax prevention.
• The roles of plasmids pXO1 (toxin) and pXO2 (capsule) in vaccine efficacy are not fully understood.

Purpose of the Study:

• To evaluate the efficacy of live, attenuated Bacillus anthracis strains with different plasmid compositions as vaccines.
• To determine the necessity of the toxin plasmid (pXO1) for protection against anthrax.
• To assess the immune response, including antibody titers, to anthrax toxin components.

Main Methods:

• Live, attenuated B. anthracis strains lacking pXO2, pXO1, or both were used for immunization.
• Immunized Fischer 344 rats were challenged with anthrax toxin intravenously.
• Immunized Hartley guinea pigs were challenged with virulent anthrax spores via aerosol or intramuscular routes.
• Antibody titers to protective antigen, lethal factor, and edema factor were measured.

Main Results:

• Animals immunized with toxigenic, non-encapsulated (pXO1+, pXO2-) strains survived toxin and spore challenge.
• These successful immunizations correlated with antibody titers to all three anthrax toxin components.
• Immunization with nontoxigenic, encapsulated (pXO1-, pXO2+) strains did not confer protection or elicit toxin-specific antibodies.

Conclusions:

• Live, attenuated B. anthracis strains must possess the toxin plasmid pXO1 to be effective vaccines.
• The presence of pXO1 enables the production of essential toxin components, crucial for protective immunity.
• Successful immunization against anthrax requires attenuated strains capable of eliciting an immune response to pXO1-encoded toxins.